Advertisement
Advertisement
U.S. markets close in 5 hours 55 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Teva Pharmaceutical Industries Limited (TEVA)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
8.56-0.09 (-0.98%)
As of 10:05AM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close8.64
Open8.60
Bid8.58 x 800
Ask8.59 x 3200
Day's Range8.52 - 8.64
52 Week Range7.73 - 13.30
Volume832,170
Avg. Volume10,468,391
Market Cap9.711B
Beta (5Y Monthly)1.30
PE Ratio (TTM)12.96
EPS (TTM)0.66
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateNov 27, 2017
1y Target Est11.36
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
11% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for TEVA

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Teva Pharmaceutical Industries
    Analyst Report: Teva Pharmaceutical Industries LimitedBased in Israel, Teva is one of the world’s largest generic drug manufacturers, with over 3,500 products marketed in over 60 countries. While a majority of its revenue is attributed to prescription generic drugs, Teva develops and markets its own branded specialty and biopharmaceutical products, primarily in the U.S. and in Europe. The company’s branded portfolio generates one fifth of total revenue and consists of patented therapies targeting central nervous system conditions (Austedo, Ajovy, Copaxone), oncology (Bendeka/Treanda), and respiratory conditions (ProAir, Qvar). While global competition has facilitated the commodification of small-molecule generic drugs, Teva’s portfolio rationalization has resulted in less overall price erosion versus peers.
    Rating
    Fair Value
    Economic Moat
    last monthMorningstar
View more
Advertisement
Advertisement